Australian biotech firm reaffirms commitment to making AstraZeneca COVID-19 vaccine

2021-10-14 12:36:05 GMT2021-10-14 20:36:05(Beijing Time) Xinhua English

SYDNEY, Oct. 14 (Xinhua) -- Australia's biotech giant CSL reaffirmed Thursday that the agreement for the production of about 50 million doses of AstraZeneca COVID-19 vaccine will be fulfilled, and that manufacturing will go on into 2022.

The announcement came after reports saying the AstraZeneca vaccine will not be manufactured in Australia due to people's preference for some other vaccines such as Pfizer and Moderna.

"Notwithstanding the perhaps disproportionate criticism that this vaccine's reputation has experienced, we could not be prouder that the AstraZeneca vaccine has given protection to many millions of Australians, and even more will be sent to support our neighbors in the region," CSL told investors in a statement.

According to the Australian government's vaccine agreement, a total of 50 million doses of AstraZeneca vaccines will be manufactured in Australia. The company has produced over 20 million doses, and it is expected that the remaining production will be completed early next year.

Australian Health Minister Greg Hunt confirmed the CSL and AstraZeneca would complete the contract, but he hinted that the contract would not be extended beyond the 50 million doses and the company has commitments to manufacture other medicines and vaccines. Enditem

| PRINT | RSS